Phase 3Data readout

Delpacibart Etedesiran (Del-desiran) (AOC 1001)

Myotonic Dystrophy Type 1 (DM1)

NVSNovartis

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Delpacibart Etedesiran (Del-desiran) (AOC 1001)
Development stage: Phase 3
Event type: Data readout
Indication: Myotonic Dystrophy Type 1 (DM1)

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for Delpacibart Etedesiran (Del-desiran) (AOC 1001) in Myotonic Dystrophy Type 1 (DM1). The expected timing is based on the latest available company guidance and may change.

Development notes

Asset from Avidity acquisition. MARINA, MARINA-OLE, HARBOR trials. 10/3/24- FDA lifted clinical hold. 7/28/25- Completed enrollment in HARBOR trial. 11/10/25- MARINA-OLE publication in Q4'25. 54wk topline data in H2 2026. 02/26/26:- MDA 2026 posters on DM1 patient journey and del-desiran MARINA-OLE treatment-experience interviews on March 9, 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source